Karl Naegler appointed General Partner at Ventech, a team sponsored by Natixis Private Equity
Karl Naegler joins Ventech, as a General Partner on September 1, 2009. This appointement enables Ventech to pursue its Internationalizing efforts by complementing its Life Science team.
Prior to Ventech, Karl Naegler worked with Atlas Venture (London and Munich) for close to eight years, where he was instrumental in the formation and financing of several start ups across Europe. He notably worked closely with U3 Pharma, prior to its acquisition by Daiichi Sankyo Co., Ltd. in 2008 and served on the Board of Directors of Nitec Pharma and Lumavita. Previously, he worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg, France.
Karl Naegler, 36 years old, holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine Berlin. He holds an MSc in Biology from the Free University of Berlin and prepared his thesis at Monash University in Melbourne, Australia. During his successful academic career he contributed to several publications in highly respected scientific journals, including Science and FASEB.
His international background and business driven approach fit very well with the Investment strategy developed by Ventech in that sector. In the Healthcare sector, Ventech mainly focuses on companies where sustainable international syndicates could be put in place and where a partial or complete asset monetization could be expected within a few years. Together with Mounia Chaoui and Laurent Assaraf, Karl Naegler will take care of the several remaining investments to be done in the Healthcare sector. Ventech Capital III has already invested in three Biotech companies: Actogenix (Belgium), Cellerix (Spain) and X2 (Germany) ; and a fourth deal is under completion.
Ventech, sponsored by Natixis Private Equity, is a Venture Capital firm with €365 M assets under management that, for more than a decade, has invested in recently formed companies or start-ups. These investments focus on the Life Science and Information Technology sectors, in France and Europe. Its latest fund Ventech Capital III, a €150 M fund, was closed in late 2007. For more information: www.ventechvc.com
Contacts
Related links
About Groupe BPCE
Groupe BPCE is the second-largest banking group in France. Through its 100,000 staff, the group serves 35 million customers – individuals, professionals, companies, investors and local government bodies – around the world. It operates in the retail banking and insurance fields in France via its two major networks, Banque Populaire and Caisse d’Epargne, along with Banque Palatine and Oney. It also pursues its activities worldwide with the asset & wealth management services provided by Natixis Investment Managers and the wholesale banking expertise of Natixis Corporate & Investment Banking. The Group's financial strength is recognized by four credit rating agencies with the following senior preferred LT ratings: Moody's (A1, stable outlook), Standard & Poor's (A, stable outlook), Fitch (AA-, negative outlook) and R&I (A+, stable outlook).
The press area was created by BPCE in order to make it easier for professionals to access Groupe BPCE press releases, images, videos, computer graphics, etc. (hereafter referred to collectively as the “Content”). This Content can be used to illustrate all publications, reports, articles or, more generally, any document or medium designed to inform the public of Groupe BPCE’s activity. You are not allowed to use the Content for commercial or publicity purposes. You are not allowed to modify the Content (except for changes of format). The Content is regularly updated by BPCE, therefore you should frequently access the press area in order to ensure you use the latest version of the Content. Your attention is also drawn to the fact that the Content contains elements considered to be intellectual works protected by copyright law and notably by France’s intellectual property code. Consequently, the photo credit (shown at the bottom right of the photo) and the mention [source BPCE] must be displayed in all publications (printed or electronic). Any user who fails to respect these conditions shall be liable vis-à-vis BPCE, the author of the Content or his/her beneficiaries and, where applicable, the persons whose image is reproduced in the Content. By downloading and, more generally, using all or part of the Content you agree to these terms.